

Adakveo Market Analysis: Competitive Scenario, Key Players, and Strategic Growth Opportunities

*The Business Research Company's
Adakveo Market Analysis: Competitive
Scenario, Key Players, and Strategic
Growth Opportunities*

LONDON, GREATER LONDON, UNITED
KINGDOM, July 9, 2026

/EINPresswire.com/ -- "The adakveo
market is dominated by a mix of
branded biologic manufacturers
focused on sickle cell disease
treatment innovation and vaso-
occlusive crisis management.

Companies are focusing on biologic therapy advancement, clinical development initiatives, patient access expansion, treatment adoption strategies, and commercial portfolio strengthening to enhance market presence and address evolving therapeutic requirements. Emphasis on disease burden reduction, long-term treatment effectiveness, healthcare



Market expansion is
supported by growth in
sickle cell patient
population, expansion of
access programs"

*The Business Research
Company*


accessibility, and compliance with regulatory standards remains central to competitive positioning. Understanding the competitive landscape is essential for stakeholders seeking growth opportunities, treatment advancement, and strategic expansion within the evolving sickle cell disease therapeutics ecosystem.

Which Market Player Is Leading The Adakveo Market?

•According to our research, Novartis AG led global sales in 2024 with a 100% market share. The company's adakveo

portfolio, which is directly involved in the Adakveo market, provides targeted biologic treatment solutions that support vaso-occlusive crisis reduction, improve disease management strategies, and strengthen therapeutic availability across sickle cell disease patient populations.

Who Are The Major Players In The Adakveo Market?



Key company operating in the adakveo market is Novartis AG.

How Concentrated Is The Adakveo Market?

- The market is highly concentrated, with the top player accounting for 100% of total market revenue in 2024. This level of concentration reflects significant regulatory and commercialization barriers, driven by specialized biologic development requirements, clinical validation standards, limited therapeutic competition, and the need for advanced manufacturing and distribution capabilities. Leading players such as Novartis AG hold dominant market share through proprietary biologic portfolios, established commercial infrastructure, global healthcare presence, and continued investment in rare disease treatment development. As demand for targeted sickle cell disease therapies, improved patient management approaches, and broader treatment accessibility increases, therapeutic advancement, market expansion initiatives, and healthcare network strengthening are expected to reinforce the competitive positioning of leading companies in the market.

- Leading companies include:

- oNovartis AG (100%)

Request A Free Sample Of The Adakveo Market Report

https://www.thebusinessresearchcompany.com/sample_request?id=19955&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jul_PR

Who Are The Key Raw Material Suppliers In The Adakveo Market?

- Major raw material suppliers in the adakveo market include Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Lonza Group, Danaher Corporation, Avantor Inc., Repligen Corporation, Wacker Chemie AG, FUJIFILM Irvine Scientific, AGC Biologics, Roquette Frères, Evonik Industries AG, DuPont, Corning Incorporated, Bio-Rad Laboratories, Eppendorf SE, 3M Company, Asahi Kasei Corporation, Charles River Laboratories International Inc., Boehringer Ingelheim BioXcellence.

Who Are The Major Wholesalers And Distributors In The Adakveo Market?

- Major wholesalers and distributors in the adakveo market include McKesson Specialty Health, McKesson Plasma and Biologics, Cardinal Health, ASD Specialty Healthcare, Cencora, CVS Specialty, Accredo Health Group, Optum Specialty Pharmacy, BioCareSD, Onco360, CuraScript SD, Amerita Specialty Infusion, AllianceRx Walgreens Pharmacy, Shields Health Solutions, Kroger Specialty Pharmacy, Senderra Specialty Pharmacy, PANTHERx Rare Pharmacy, CarelonRx Specialty Pharmacy, FFF Enterprises Inc., Morris & Dickson Co. LLC.

Who Are The Major End Users Of The Adakveo Market?

- Major end users in the adakveo market include Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, St. Jude Children's Research Hospital, Memorial Sloan Kettering Cancer Center, Mount Sinai Health System, Duke University Health System, Vanderbilt University Medical Center, Yale New Haven Health, Stanford Health Care, Northwestern Memorial Hospital, Houston Methodist

Hospital, UC Davis Health, Children's National Hospital, City of Hope, NYU Langone Health, Cedars-Sinai Medical Center, Montefiore Medical Center, Tampa General Hospital, Massachusetts General Hospital.

What Are The Major Competitive Trends In The Market?

- Regulatory authorization changes are transforming the adakveo market by influencing commercial availability, treatment accessibility, and competitive dynamics in sickle cell disease therapeutics.
- Example: In August 2023, Novartis AG announced the removal of adakveo (crizanlizumab) from European Union and European Economic Area markets after the European Commission adopted a decision endorsing the CHMP recommendation to revoke its conditional marketing authorization.
- The regulatory action, driven by Phase III STAND study findings, impacts regional market presence, influences treatment adoption patterns, and reshapes commercialization strategies within the sickle cell disease treatment landscape.

Which Strategies Are Companies Adopting To Stay Ahead?

- Targeted Biologic Therapies Advancing Sickle Cell Disease Management
- Clinical Evidence Expansion Supporting Long-Term Treatment Optimization
- Precision Therapeutics Improving Vaso-Occlusive Crisis Prevention Strategies
- Patient Access Initiatives Expanding Specialty Treatment Availability
- Research Investments Strengthening Next-Generation Hematology Innovation

Access The Detailed Adakveo Market Report Here

https://www.thebusinessresearchcompany.com/report/adakveo-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jul_PR

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 30,000+ reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/925419655>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.